Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

Tempus AI (TEM) has entered into a definitive agreement to acquire Personalis (PSNL) for $16.25 per share, representing a total enterprise value of $1.5 billion. The offer represents a 28% premium to the unaffected 30-day VWAP and will be structured as a 100% stock transaction with a floating exchange ratio, subject to a maximum and with an option for Tempus to pay up to 50% in cash.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.